Cleveland Clinic, Case Western Reserve University
47 papers in the library · 564 citations · publishing 1968-2026
JAMA Psychiatry July 15, 2026 Brian S. Barnett, Franklin King
This Viewpoint reviews the case of sodium oxybate, a product of gamma-hydroxybutyrate (GHB), to illustrate how psychedelics and other Schedule I substances can proceed through a similar regulatory pathway.
The Primary Care Companion For CNS Disorders June 25, 2026 Franklin King, Juliana Zambrano, Erin Mauney et al.
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...
The Primary Care Companion For CNS Disorders June 23, 2026 Franklin King, Brian S. Barnett, S Trevor Taylor et al.
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...
Psychedelic Medicine June 1, 2026 Brian S. Barnett, Akhil Anand, Jeremy Weleff et al.
Little is known about the correlates of repeated non-medical lysergic acid diethylamide (LSD) use. Therefore, we aimed to determine the prevalence and correlates of past-year LSD use among people aged 18 years and older in the United States who first used LSD at least 5 years ago. Using data from the 2015-2019 National Survey on Drug Use and Health, we examined the estimated weighted prevalence...
medRxiv Preprint Server April 28, 2026 Sandeep M. Nayak, Nathan D. Sepeda, Matthew Nielsen Dick et al. preprint
Background Psilocybin has increasingly been studied as a therapeutic for psychiatric and neurologic conditions, yet comprehensive cardiovascular safety data are limited. Current trials often exclude individuals with blood pressure ≥140/90 mmHg, criteria established conservatively without robust empirical support.
Annals of Clinical Psychiatry March 10, 2026 Brian S. Barnett
Background Though esketamine was approved by the Food and Drug Administration (FDA) for treatment-resistant depression in 2019, there is no published research on implementation challenges. Therefore, the aim of this study was to investigate online commentary about these challenges among mental healthcare providers. Methods Using the terms “esketamine” and “Spravato”, the author searched social...
Psychedelic Medicine March 1, 2026 Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey et al.
Objective: While data on perceived availability of lysergic acid diethylamide (LSD) [paLSD] are collected annually in the United States, detailed investigations of recent trends in paLSD have not been published. Therefore, we sought to explore this topic. Method: Data were sourced from the 2015–2019 National Survey on Drug Use and Health (NSDUH) administrations. To identify factors associated...
CNS Drugs January 17, 2026 Gaëlle Rached, Anna Campana, Dimitri Fiani et al. 1 citation
Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns about potential drug interactions and...
Psychedelic Medicine December 30, 2025 Brian S. Barnett, Akhil Anand, Tatiana Falcone et al.
Objective: This study aimed to characterize changes in estimated past-year lysergic acid diethylamide (LSD) use among sexual minorities in the United States using nationally representative data and to compare correlates of LSD use between lesbian, gay, and bisexual individuals (LGB) and heterosexual individuals. Method: Using National Survey on Drug Use and Health data on adults from 2015 to...
The Journal of Clinical Psychiatry September 3, 2025 Kristina T. Kumpf, Samuel T. Wilkinson, Bo Hu et al.
Electroconvulsive therapy (ECT) has potent antidepressant effects yet can lead to neurocognitive side effects. Ketamine is a rapid-acting antidepressant, which may be an alternative to ECT. Few have directly compared the cognitive effects of ECT and ketamine treatment. We compared cognitive effects of intravenous ketamine and ECT in patients with treatment-resistant depression (TRD), collected...
Journal of Psychoactive Drugs July 2, 2025 Brian S. Barnett, Miranda Arakelian, Jeremy Weleff et al. 2 citations
This study evaluated the attitudes, knowledge, and educational experiences of psychiatry residents regarding psychedelics and psychedelic-assisted therapy (PAT). In 2023, we distributed an anonymous survey to United States psychiatry residents, assessing demographics, knowledge, and opinions on psychedelics/PAT. The survey also included items asking respondents to retrospectively self-report...
Psychedelic Medicine June 1, 2025 Rahul Katkar, Ashley M Perez, Murat Altinay et al. 4 citations
Gender-themed lysergic acid diethylamide (LSD) experiences have been documented anecdotally but not yet studied systematically. This study aimed to explore such experiences using data from Reddit to better understand their nature and potential therapeutic implications. In this retrospective observational study, posts and comments on the "r/LSD" subreddit reporting gender-themed LSD experiences...
Psychiatry Research June 1, 2025 Jeremy Weleff, Alejandra Pulido-Saavedra, Ardavan Mohammad Aghaei et al. 4 citations
Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor...
Psychedelic Medicine June 1, 2025 Olivia M Dhaliwal, Lukas Bobak, Brian S. Barnett
With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedioxymethamphetamine in the treatment of posttraumatic stress disorder, the likelihood of psychedelic medication becoming approved for clinical use in the United States is high. Psychedelic-assisted therapy (PAT) may have a high demand in rural America,...
Psychiatry Research May 1, 2025 Gerard Sanacora, Brian S. Barnett, Bo Hu et al. 2 citations
Previous studies have shown patient preference can have large effects on treatment adherence and patient satisfaction. However, the direct effects of matching treatment with patient preference on efficacy and safety outcomes remain unclear. We aimed to evaluate the effects of patient preference and preference-matching on efficacy, adverse events, and adherence to electroconvulsive therapy (ECT)...
Journal of Psychoactive Drugs March 14, 2025 Lukas Bobak, Ian Dorney, Alexsandra Kovacevich et al. 2 citations
Long COVID lacks effective pharmaceutical treatment options. Psychedelic treatment for long COVID has received attention given anecdotal reports of neuropsychiatric symptom improvement. This study investigates the use of psilocybin for neuropsychiatric long COVID symptoms, examining online accounts of individuals with reported long COVID using psilocybin. We searched the Reddit communities,...
Cleveland Clinic Journal of Medicine March 1, 2025 Franklin King, Brian S. Barnett, Erin Mauney 11 citations
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid...
Journal of Psychoactive Drugs March 1, 2025 Alexsandra Kovacevich, Ian Dorney, Lukas Bobak et al. 1 citation
Olfactory dysfunction (OD) has become increasingly prevalent since the COVID-19 pandemic, yet effective treatments remain limited. In recent years, anecdotal reports have emerged on the potential benefits of serotonergic psychedelics (lysergic acid diethylamide [LSD], psilocybin, etc.) in improving OD. To date, only one case series in the medical literature has documented this phenomenon. This...
JAMA Psychiatry February 12, 2025 Brian S. Barnett, Roger D Weiss, Gerard Sanacora 7 citations
This Viewpoint discusses challenges related to ketamine use within psychiatry and offers recommendations for optimizing patient safety.
Psychoactives February 5, 2025 Brian S. Barnett 7 citations
The author surveyed researchers about United States federal grant applications for therapeutic psychedelic research and their funding success. An anonymous survey was sent to corresponding authors of the 50 most-cited psychedelic research articles published after 2000 and also disseminated on Twitter. Ten researchers responded, reporting on 24 National Institutes of Health (NIH) grant...
Psychopharmacology 2025 Brian S. Barnett, M Frances Vest, Marcus S Delatte et al. 20 citations
There is increasing interest in establishing psychedelic research programs at academic medical centers. However, psychedelics are intensely psychoactive, carry considerable sociopolitical baggage, and most are Schedule I drugs, creating significant potential impediments to implementation. There is little formal guidance for investigators on navigating the complex on-the-ground obstacles...
medRxiv October 13, 2024 Brian S. Barnett preprint
Abstract This study surveyed researchers to assess the contents and funding success of federal grant applications for research into therapeutic applications of psychedelics in the United States. The author emailed an anonymous survey to the corresponding authors of the 50 most-cited articles on psychedelics published after 2000 and disseminated it via Twitter. Ten researchers responded,...
Journal of Psychoactive Drugs June 21, 2024 Peter Kenneth Gillman, Brian S. Barnett, Curtis J. Koons et al. 9 citations
Data on medication interactions with psychedelics are limited. Here we present what may be the first published report of a hypertensive emergency following the combination of psilocybin mushrooms with a monoamine oxidase inhibitor (MAOI). A 42-year-old man with treatment-resistant major depressive disorder took 1 g of Psilocybe cubensis mushrooms, while prescribed tranylcypromine,...
JAMA Network Open June 3, 2024 Manish Kumar Jha, Samuel T. Wilkinson, Kamini Krishnan et al. 29 citations
The ELEKT-D: Electroconvulsive Therapy (ECT) vs Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D) trial demonstrated noninferiority of intravenous ketamine vs ECT for nonpsychotic TRD. Clinical features that can guide selection of ketamine vs ECT may inform shared decision-making for patients with TRD. To evaluate whether selected clinical features were associated with...
Psychedelic Medicine June 1, 2024 Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey et al. 20 citations
Though lysergic acid diethylamide (LSD) use is rising in the United States amid expanding research into the therapeutic potential of psychedelics, little scholarly work exists on whether perceived risk of trying LSD (prLSD) is changing or factors influencing prLSD among the general public. Therefore, we sought to investigate changes in prLSD from 2015 to 2019 and identify characteristics...